Quality of life analyses in patients with multiple myeloma: results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b study

  • Gabriel Tremblay
  • , Patrick Daniele
  • , Janis Breeze
  • , Lingling Li
  • , Jatin Shah
  • , Sharon Shacham
  • , Michael Kauffman
  • , Monika Engelhardt
  • , Ajaj Chari
  • , Ajay Nooka
  • , Dan Vogl
  • , Maria Gavriatopoulou
  • , Meletios-Athanasios Dimopoulos
  • , Paul Richardson
  • , Noa Biran
  • , David Siegel
  • , Philip Vlummens
  • , Chantal Doyen
  • , Thierry Facon
  • , Mohamad Mohty
    • Nathalie Meuleman, Moshe Levy, Luciano Costa, James E Hoffman, Michel Delforge, David Kaminetzky, Katja Weisel, Marc Raab, David Dingli, Sascha Tuchman, Frenzel Laurent, Ravi Vij, Gary Schiller, Philippe Moreau, Joshua Richter, Martin Schreder, Klaus Podar, Terri Parker, Robert Frank Cornell, Karlin Lionel, Sylvain Choquet, Jagannath Sundar

Research output: Journal article (peer-reviewed) › Journal article

11   Link opens in a new tab Citations (Scopus)

Fingerprint

Dive into the research topics of 'Quality of life analyses in patients with multiple myeloma: results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b study'. Together they form a unique fingerprint.
Sort by

Pharmacology, Toxicology and Pharmaceutical Science

Medicine and Dentistry